{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:28:08Z","timestamp":1790116088241,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023326","name":"Britannia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Levodopa\u2010entacapone\u2010carbidopa intestinal gel (LECIG) infusion was introduced to the Swedish market in 2019 for Parkinson's disease (PD) with motor fluctuations. Long\u2010term data are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To study long\u2010term data on LECIG treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis of the first 24 patients receiving LECIG in Sweden from 2019 to 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five of 24 (21%) patients discontinued LECIG because of side effects, mostly diarrhea. Eight of the 24 (33%) patients died while receiving LECIG. Eleven of 24 (46%) patients were still on LECIG. Median (range) for disease and treatment duration was 19 (9\u201330) and 3.6 (3.1\u20134.0) years, respectively, whereas health\u2010related quality of life scales showed median (interquartile range; n) Parkinson's Disease Questionnaire 8\u2010item summary index scores of 38 (4; n\u2009=\u20097), EuroQol 5D scores of 0.59 (0.17; n\u2009=\u20097), and EQ\u20105D visual analogue scale scores of 65 (10; n\u2009=\u20097).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>LECIG infusion is a viable treatment option for PD patients with motor fluctuations, for up to 4\u2009years in our cohort.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mdc3.14240","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T09:24:42Z","timestamp":1729761882000},"page":"1609-1612","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A 4\u2010Year Follow\u2010Up of Levodopa\u2010Entacapone\u2010Carbidopa Intestinal Gel Treatment in Parkinson's Disease"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7139-8561","authenticated-orcid":false,"given":"Mezin","family":"\u00d6thman","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Neurology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-7715","authenticated-orcid":false,"given":"Dag","family":"Nyholm","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Neurology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9439-1"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70293-X"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04401-w"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2012.01689.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3180ed449f"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27626"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.737392"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040254"},{"issue":"11","key":"e_1_2_8_10_1","first-page":"2409","article-title":"The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia","volume":"20","author":"Guo G","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055899.24594.8E"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2009.09.034"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.1.59"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2014.10.4.281"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.02.006"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03614.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26855"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75052-2"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029526"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2005.01.007"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2021.03.047"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000158674.91134.6E"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221108018"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.11.029"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13926"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001707"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70098-3"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13948"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11269-7"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105357"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.14240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:32:18Z","timestamp":1760952738000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.14240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/mdc3.14240"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.14240","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"2024-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}